Xintela AB (OSTO:XINT) FCF Margin % : 1,107.02% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Xintela AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Xintela AB's Free Cash Flow for the three months ended in Mar. 2024 was kr3.31 Mil. Xintela AB's Revenue for the three months ended in Mar. 2024 was kr0.30 Mil. Therefore, Xintela AB's FCF Margin % for the quarter that ended in Mar. 2024 was 1,107.02%.

As of today, Xintela AB's current FCF Yield % is -26.35%.

The historical rank and industry rank for Xintela AB's FCF Margin % or its related term are showing as below:

OSTO:XINT' s FCF Margin % Range Over the Past 10 Years
Min: -822250 Med: -68230.77 Max: -1378.2
Current: -11768.17

During the past 11 years, the highest FCF Margin % of Xintela AB was -1378.20%. The lowest was -822250.00%. And the median was -68230.77%.

OSTO:XINT's FCF Margin % is ranked worse than
92.4% of 1039 companies
in the Biotechnology industry
Industry Median: -138.52 vs OSTO:XINT: -11768.17

Xintela AB FCF Margin % Historical Data

The historical data trend for Xintela AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xintela AB FCF Margin % Chart

Xintela AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-85,563.16

-68,230.77

Xintela AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-14,835.90	1,107.02

Competitive Comparison of Xintela AB's FCF Margin %

For the Biotechnology subindustry, Xintela AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xintela AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xintela AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Xintela AB's FCF Margin % falls into.

Xintela AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Xintela AB's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-53.22	/	0.078
	=	-68,230.77 %

Xintela AB's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	3.31	/	0.299
	=	1,107.02 %

Xintela AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Xintela AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Xintela AB (OSTO:XINT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xintela AB (OSTO:XINT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Medicon Village, Lund, SWE, 22381

Website

http://www.xintela.se

Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based therapies for Glioblastoma and Tripple-negative breast cancer. XSTEM is also evaluated for the treatment of the severe and deadly lung complication ARDS, which may affect covid-19 patients.

Xintela AB (OSTO:XINT) Headlines

No Headlines